Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cisplatin/gimeracil/oteracil/tegafur

Cisplatin/gimeracil/oteracil/tegafur Reactions 1680, p89 - 2 Dec 2017 Various toxicities: 2 case reports In a case series, a 75-year-old man developed thrombocytopenia and exanthema of the chest region while a 71-year-old man developed dysgeusia, appetite loss, vomiting, weight loss, thrombocytopenia and nausea during treatment with cisplatin and gimeracil/oteracil/tegafur [S-1; not all routes and dosages stated; durations of treatments to reactions onsets not stated; not all outcomes stated] Case 1: A 75-year-old man, who was diagnosed with oesophagogastric adenocarcinoma, started receiving perioperative neoadjuvant therapy with two 4-week cycles of IV cisplatin 75 mg/m on day 1 and oral gimeracil/oteracil/ tegafur 25 mg/m twice daily on days 1 21. Subsequently, he developed grade I mild thrombocytopenia and grade II mild exanthema of the chest region. No further adverse events were noted. In early December 2016, he underwent a successful radical gastrectomy with lymph node dissection. Following the surgery, he was administered two cycles of cisplatin and gimeracil/oteracil/tegafur uneventfully. Case 2: A 71-year-old man, who was diagnosed with oesophagogastric adenocarcinoma, started receiving perioperative neoadjuvant therapy with two 4-week cycles of IV cisplatin and gimeracil/oteracil/tegafur. Subsequently, he developed grade II dysgeusia, grade II appetite loss and grade II mild recurring episodes of vomiting. They http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Cisplatin/gimeracil/oteracil/tegafur

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Download PDF
1 page

Cisplatin/gimeracil/oteracil/tegafur

Abstract

Reactions 1680, p89 - 2 Dec 2017 Various toxicities: 2 case reports In a case series, a 75-year-old man developed thrombocytopenia and exanthema of the chest region while a 71-year-old man developed dysgeusia, appetite loss, vomiting, weight loss, thrombocytopenia and nausea during treatment with cisplatin and gimeracil/oteracil/tegafur [S-1; not all routes and dosages stated; durations of treatments to reactions onsets not stated; not all outcomes stated] Case 1: A 75-year-old man, who was...
Loading next page...
1
 
/lp/springer_journal/cisplatin-gimeracil-oteracil-tegafur-xmY1i0upCV

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-017-39020-9
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p89 - 2 Dec 2017 Various toxicities: 2 case reports In a case series, a 75-year-old man developed thrombocytopenia and exanthema of the chest region while a 71-year-old man developed dysgeusia, appetite loss, vomiting, weight loss, thrombocytopenia and nausea during treatment with cisplatin and gimeracil/oteracil/tegafur [S-1; not all routes and dosages stated; durations of treatments to reactions onsets not stated; not all outcomes stated] Case 1: A 75-year-old man, who was diagnosed with oesophagogastric adenocarcinoma, started receiving perioperative neoadjuvant therapy with two 4-week cycles of IV cisplatin 75 mg/m on day 1 and oral gimeracil/oteracil/ tegafur 25 mg/m twice daily on days 1 21. Subsequently, he developed grade I mild thrombocytopenia and grade II mild exanthema of the chest region. No further adverse events were noted. In early December 2016, he underwent a successful radical gastrectomy with lymph node dissection. Following the surgery, he was administered two cycles of cisplatin and gimeracil/oteracil/tegafur uneventfully. Case 2: A 71-year-old man, who was diagnosed with oesophagogastric adenocarcinoma, started receiving perioperative neoadjuvant therapy with two 4-week cycles of IV cisplatin and gimeracil/oteracil/tegafur. Subsequently, he developed grade II dysgeusia, grade II appetite loss and grade II mild recurring episodes of vomiting. They

Journal

Reactions Weekly – Springer Journals

Published: Dec 2, 2017

There are no references for this article.